Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody designed to selectively bind to the programmed death-1 (PD-1) receptor with a dissociation constant (KD) of 74 pM. By inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, Sintilimab effectively restores the body's endogenous antitumor T-cell response. Research indicates that when combined with prebiotics, Sintilimab effectively reduces tumor volume and modulates the balance of immune cell subpopulations in mouse models of lung adenocarcinoma. This antibody is primarily used in the investigation of classical Hodgkin's lymphoma, non-small cell lung cancer, and esophageal cancer, making it a valuable tool for oncological research and therapeutic explorations.
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody designed to selectively bind to the programmed death-1 (PD-1) receptor with a dissociation constant (KD) of 74 pM. By inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, Sintilimab effectively restores the body's endogenous antitumor T-cell response. Research indicates that when combined with prebiotics, Sintilimab effectively reduces tumor volume and modulates the balance of immune cell subpopulations in mouse models of lung adenocarcinoma. This antibody is primarily used in the investigation of classical Hodgkin's lymphoma, non-small cell lung cancer, and esophageal cancer, making it a valuable tool for oncological research and therapeutic explorations.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
